

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(formerly known as ASIA PACIFIC SILK ROAD INVESTMENT COMPANY LIMITED 亞太絲路投資有限公司)

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
REGISTRATION OF IMPORTANT PATENTS RELATED
TO CANCER SCREENING APPROVED BY THE PATENT REGISTRY
OF THE INTELLECTUAL PROPERTY DEPARTMENT OF
THE GOVERNMENT OF THE HONG KONG
SPECIAL ADMINISTRATIVE REGION**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that important patents related to advanced and non-invasive detection technologies for cancer screening and monitoring owned by the Asian Advanced Medical Testing Center have been registered with the Patent Registry of the Intellectual Property Department of the Government of the Hong Kong Special Administrative Region. Details of the patents are set out below:

Patent Name:	A method for the direct isolation of peripheral blood mononuclear cells enriched with circulating tumour cells for use in liquid biopsy
Type:	Invention Patent
Patent Number:	30036746 A

Date of Application: 9 February 2021

Date of Expiry: 9 February 2029

The technology associated with this patent effectively isolates circulating tumour cells directly from peripheral blood for use in liquid biopsy, which simplifies the isolation process for enrichment of circulating tumour cells and improves the recovery efficiency of circulating tumour cells, thus solving the technical bottleneck of losing large numbers of circulating tumour cells with the existing technology.

Patent Name: A multiplex immunofluorescence staining and bioimaging method for circulating tumour cells for use in liquid biopsy

Type: Invention Patent

Patent Number: 30036745 A

Date of Application: 9 February 2021

Date of Expiry: 9 February 2029

The technology associated with the patent allows multiple immunofluorescence staining of circulating tumour cells and the use of optical bioimaging to effectively detect and accurately distinguish multiple types of circulating tumour cells, thus improving the sensitivity and specificity of circulating tumour cell detection, especially so when the number of circulating tumour cells is relatively low.

The technology related to the patents strengthens the leading status of the Company in longevity medical testing by significantly improving the effectiveness and accuracy of early cancer screening, which will help to prevent and treat cancer effectively.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 11 May 2021

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)

Mr. Wang Hongxin (*Chief Executive Officer*)

Mr. Yeung Siu Keung

Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Tam Ho Leung Simon

Ms. Wang Weixia

Mr. Chai Nan

Non-executive Director

Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.